ENGNW

enGene Holdings Inc. Warrants

Near 52W High

$0.23+$0.05 (+27.71%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Scan Active Universe on Day Trade Edge

Key Statistics

Market Cap—

Forward P/E—

EPS (TTM)—

52-Week Return—

50-Day Moving Avg—

200-Day Moving Avg—

Volume Today842

Avg Volume842

Day Range$0.23 – $0.25

52-Week Range$0.23 – $0.25

Open Price$2.10

Previous Close$0.18

Company Profile

Description

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

CEO

Mr. Ronald H. W. Cooper

Website

engene.com

SEC Filings

EDGAR Filings

Exchange Listing

Nasdaq.com